Rohling R G, Zimmermann A P, Breymann C
Institute of Anesthesiology, Division of Obstetrics and Perinatal Physiology, University Hospital Zurich, Switzerland.
J Hematother Stem Cell Res. 2000 Aug;9(4):497-500. doi: 10.1089/152581600419161.
To compare two modalities of iron supplementation for the preoperative stimulation of erythropoiesis using recombinant human erythropoietin (rhEPO), 12 adults in normal hemoglobin and iron status due for elective surgery were randomized to rhEPO 200 U/kg body weight subcutaneously twice weekly combined with either iron sucrose 200 mg intravenously twice weekly or iron sulfate 160 mg/day orally, for 3 weeks preoperatively. Efficacy was measured by the increases over baseline in hemoglobin, reticulocyte count, and ferritin determined 3 days before surgery; preoperative reticulocyte count and ferritin were significantly higher with intravenous iron, whereas the only significant intragroup increases in hemoglobin between time points also occurred in this group. Intravenous iron significantly boosts the hematopoietic response to rhEPO and prevents iatrogenic iron depletion in otherwise healthy candidates for elective surgery.
为比较两种铁补充方式对使用重组人促红细胞生成素（rhEPO）进行术前红细胞生成刺激的效果，将12名血红蛋白和铁状态正常、计划进行择期手术的成年人随机分为两组，一组每周皮下注射两次rhEPO，剂量为200 U/kg体重，同时每周静脉注射两次200 mg蔗糖铁；另一组每周皮下注射两次rhEPO，剂量为200 U/kg体重，同时每天口服160 mg硫酸亚铁，术前治疗3周。通过手术前3天测定的血红蛋白、网织红细胞计数和铁蛋白相对于基线水平的增加来衡量疗效；静脉补铁组术前网织红细胞计数和铁蛋白显著更高，而且该组在各时间点之间血红蛋白唯一显著的组内增加也出现在该组。静脉补铁可显著增强对rhEPO的造血反应，并防止在其他方面健康的择期手术候选者出现医源性铁缺乏。
